Uveal Melanoma
Recent clinical, regulatory, research and industry developments relating to this disease.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q1 2027.
- 1 industry development reported.
- Q1 2027IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
- Q3 2027Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal Melanoma
- Q1 2030A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Q4 2030A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
- Q4 2032Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
Clinical MilestonesViewHide
- 2026-03-17A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal MelanomaResults posted
- 2026-02-11A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal MelanomaResults posted
- 2026-06-30Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)Results expected Q4 2032
- 2026-06-12Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal MelanomaResults expected Q3 2027
- 2026-05-06A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)Results expected Q4 2030
- 2026-04-02A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaResults expected Q1 2030
- 2026-02-17IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)Results expected Q1 2027
Industry & MarketViewHide
- 2026-02-23CRISPR-Cas13d-mediated targeting of RasGRP3 shows selective anticancer effects in uveal melanomaIndustry · BioWorld Gene Therapy
- 2026-06-30ClinicalAdjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)Results expected Q4 2032
- 2026-06-12ClinicalNeoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal MelanomaResults expected Q3 2027
- 2026-05-06ClinicalA Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)Results expected Q4 2030
- 2026-04-02ClinicalA Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaResults expected Q1 2030
- 2026-03-17ClinicalA Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal MelanomaResults posted
- 2026-02-23IndustryCRISPR-Cas13d-mediated targeting of RasGRP3 shows selective anticancer effects in uveal melanomaIndustry · BioWorld Gene Therapy
- 2026-02-17ClinicalIDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)Results expected Q1 2027
- 2026-02-11ClinicalA Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal MelanomaResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A… (2022)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Melanoma4
- Uveal Neoplasms4
- Antineoplastic Combined Chemotherapy Protocols1
- Choroid Neoplasms1
- Circulating Tumor DNA1
- DNA Methylation1
- Gene Expression Regulation, Neoplastic1
- Immune Checkpoint Inhibitors1
Leading journals5
- Cancer cell1
- Frontiers in immunology1
- Nature communications1
- Ophthalmology1
- The New England journal of medicine1
Leading researchers8
- Coupland SE2
- Hassel JC2
- Piperno-Neumann S2
- Roman-Roman S2
- Stern MH2
- Abdel-Rahman MH1
- Akbani R1
- Babur O1
Affiliations (unnormalised)6
- Institut Curie2
- University Hospital Essen2
- Bavarian Cancer Research Center (BZKF)1
- Buck Institute for Research on Aging1
- Canada's Michael Smith Genome Sciences Centre1
- Center for Biomolecular Sciences and Engineering1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Uveal melanoma is a rare malignant melanoma that arises from melanocytes in the uvea of the eye. It is an ocular melanoma rather than a cutaneous melanoma, and the literature focuses on its biology, prognosis, and treatment approaches.
The supplied grounding does not identify a specific cause or aetiology for uveal melanoma. It only defines the disease as a malignant melanoma arising from uveal melanocytes.
The disease originates from malignant transformation of melanocytes in the uveal tract. The grounding does not provide additional mechanistic detail about molecular drivers or downstream biological pathways.
The supplied grounding does not specify risk factors for uveal melanoma.
The supplied grounding does not provide treatment guidance or standard-of-care modalities for uveal melanoma.
AI-generated summary grounded in MeSH. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A rare, malignant MELANOMA arising from the melanocytes of the UVEA.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.